Emerging drugs for the treatment of bone metastasis

Bibliography

• Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
   PubMed Web of Science ®Google Scholar
• Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005;15:57-62
   PubMed Web of Science ®Google Scholar
• Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-80
   PubMed Web of Science ®Google Scholar
• Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17
   PubMed Web of Science ®Google Scholar
• Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress OBL adhesion and differentiation. Clin Exp Metastasis 2004;21:427-35
   PubMed Web of Science ®Google Scholar
• Bu G, Lu W, Liu CC, et al. Breast cancer-derived Dickkopf1 inhibits OBL differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008;123:1034-42
   PubMed Web of Science ®Google Scholar
• Mastro AM, Gay CV, Welch DR, et al. Breast cancer cells induce OBL apoptosis: a possible contributor to bone degradation. J Cell Biochem 2004;91:265-76
   PubMed Web of Science ®Google Scholar
• Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote Osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-60
   PubMed Web of Science ®Google Scholar
• Hall CL, Kang S, MacDougald OA, et al. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97:661-72
   PubMed Web of Science ®Google Scholar
• Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol 2012;4:87-93
   PubMedGoogle Scholar
• Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49:71-6
   PubMed Web of Science ®Google Scholar
• Coleman R, Gnant M, Morgan G, et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059-67
   PubMed Web of Science ®Google Scholar
• Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014;15:997-06
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7
   PubMed Web of Science ®Google Scholar
• Coleman RE, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013;24:398-05
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hemdezet TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55
   PubMed Web of Science ®Google Scholar
• Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to. 2017. Available from: http://www.prnewswire.com/news-releases/bone-metastases-therapeutics---pipeline-assessment-and-market-forecasts-to-2017-129361548.html [Last Accessed 06 September 2015]
   Google Scholar
• Hussein O, Komarova SV. Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal 2011;5:85-99
   PubMed Web of Science ®Google Scholar
• Gamero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-52
   PubMed Web of Science ®Google Scholar
• Brubaker KD, Vessella RL, True LD, et al. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18:222-30
   PubMed Web of Science ®Google Scholar
• Le Gall C, Bellahcne A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894-02
   PubMed Web of Science ®Google Scholar
• Withana NP, Blum G, Sameni M, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012;72:1199-09
   PubMed Web of Science ®Google Scholar
• Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010;10:452-8
   PubMed Web of Science ®Google Scholar
• Liu XH, Kirschenbaum A, Yao S, et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 2005;146:1991-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103-7
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V, et al. OCL differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98-02
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massagu J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84
   PubMed Web of Science ®Google Scholar
• Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kfl (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 2011;6:e19234
   PubMed Web of Science ®Google Scholar
• Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2011;226:780-4
   PubMed Web of Science ®Google Scholar
• Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006;12:1372-9
   PubMed Web of Science ®Google Scholar
• Akiyama T, Shimo Y, Yanai H, et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008;29:423-37
   PubMed Web of Science ®Google Scholar
• Knoop KA, Kumar N, Butler BR, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol 2009;183:5738-47
   PubMed Web of Science ®Google Scholar
• Tatarov O, Mitchell TJ, Seywright M, et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540-9
   PubMed Web of Science ®Google Scholar
• Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004;23:790-9
   PubMed Web of Science ®Google Scholar
• Chang YM, Bai L, Lin S, et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZDO53O. Oncogene 2008;27:6365-75
   PubMed Web of Science ®Google Scholar
• Yang JC, Ok JH, Busby JE, et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60
   PubMed Web of Science ®Google Scholar
• de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZDO53O reversibly inhibits the formation and activity of human OCLs. Mol Cancer Res 2009;7:476-88
   PubMed Web of Science ®Google Scholar
• Moy B, Neven P, Lebrun F, et al. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 2014;19:348-9
   PubMed Web of Science ®Google Scholar
• Araujo JC, Poblenz A, Corn P, et al. Dasatinib inhibits both OCL activation and prostate cancer PC-3-cell-induced OCL formation. Cancer Biol Ther 2009;8:2153-9
   PubMed Web of Science ®Google Scholar
• Brownlow N, Mol C, Hayford C, et al. Dasatinib is a potent inhibitor of tumour-associated macrophages, OCLs and the FMS receptor. Leukemia 2009;23:590-4
   PubMed Web of Science ®Google Scholar
• Lee YC, Huang CF, Murshed M, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of OBLs. Oncogene 2010;29:3196-07
   PubMed Web of Science ®Google Scholar
• Vandyke K, Dewar AL, Farrugia AN, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994-7
   PubMed Web of Science ®Google Scholar
• Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of OCLs in vivo. J Bone Miner Res 2010;25:1759-70
   PubMed Web of Science ®Google Scholar
• Koreckij T, Nguyen H, Brown LG, et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263-8
   PubMed Web of Science ®Google Scholar
• Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-87
   PubMed Web of Science ®Google Scholar
• Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 2013;14:1307-16
   PubMed Web of Science ®Google Scholar
• Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signalling in OBLs regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006;119:1283-96
   PubMed Web of Science ®Google Scholar
• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKKI suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11
   PubMed Web of Science ®Google Scholar
• Iyer SP, Beck JT, Stewart AK, et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 2014;167:366-75
   PubMed Web of Science ®Google Scholar
• Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for OCL induction. Biochem Biophys Res Commun 2000;268:2-7
   PubMed Web of Science ®Google Scholar
• Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006;23:117-22
   PubMed Web of Science ®Google Scholar
• Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010;107:5124-9
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009;24:744-52
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol 2014;165:814-23
   PubMed Web of Science ®Google Scholar
• Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Lin SH. OBLs in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8
   PubMed Web of Science ®Google Scholar
• Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66
   PubMed Web of Science ®Google Scholar
• Nelson JB, Fizazi K, Miller K, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012;118:5709-18
   PubMed Web of Science ®Google Scholar
• Fizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31:1740-7
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1- dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010;9:9
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-17
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Xia Z, Lau YS, et al. Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochem Biophys Res Commun 2006;350:478-83
   PubMed Web of Science ®Google Scholar
• Aenlle KK, Curtis KM, Roos BA, et al. Hepatocyte growth factor and p38 promote osteogenic differentiation of human mesenchymal stem cells. Mol Endocrinol 2014;28:722-30
   PubMed Web of Science ®Google Scholar
• Chen HT, Tsou HK, Chang CH, et al. Hepatocyte growth factor increases osteopontin expression in human OBLs through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS ONE 2012;7:e38378
   PubMed Web of Science ®Google Scholar
• Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for OCLs and OBLs in vitro. Proc Natl Acad Sci U S A 1996;93:7644-8
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-19
   PubMed Web of Science ®Google Scholar
• Smith MR, De Bono JS, Sternberg CN, et al. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). Genitourinary Cancers Symposium 2015
   Google Scholar
• Giubellino A, Linehan WM, Bottaro DP. Targeting the met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009;9:785-93
   PubMed Web of Science ®Google Scholar
• Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009;27:3225-34
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014;25:1603-8
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
   PubMed Web of Science ®Google Scholar
• Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. J Endocrinol 2012;215:221-37
   PubMed Web of Science ®Google Scholar
• Liu LL, Xie N, Sun S, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2014;33:3140-50
   PubMed Web of Science ®Google Scholar
• Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012;360:38-43
   PubMed Web of Science ®Google Scholar
• Drake JM, Graham NA, Stoyanova T, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 2012;109:1643-64
   PubMed Web of Science ®Google Scholar
• De Bono S, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-05
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem 1995;38:4191-7
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25
   PubMed Web of Science ®Google Scholar
• Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507-16
   PubMed Web of Science ®Google Scholar
• Iuliani M, Pantano F, Buttigliero C, et al. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget 2015;6(14):12520-8
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28
   PubMed Web of Science ®Google Scholar
• Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009;69:3955-62
   PubMed Web of Science ®Google Scholar
• Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote OCL survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003;10:1165-77
   PubMed Web of Science ®Google Scholar
• Mogi M, Kondo A. Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun 2009;384:82-6
   PubMed Web of Science ®Google Scholar
• Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by OCLs. Bone 2004;35:1144-56
   PubMed Web of Science ®Google Scholar
• Smink JJ, Leutz A. Rapamycin and the transcription factor C/EBPbeta as a switch in OCL differentiation: implications for lytic bone diseases. J Mol Med (Berl) 2010;88:227-33
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Gnant M, Baselga J, Rugo HS, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 2013;105:654-63
   PubMed Web of Science ®Google Scholar
• Maass N, Harbeck N, Mundhenke C, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol 2013;139:2047-56
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637-43
   PubMed Web of Science ®Google Scholar
• Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 1996;37:249-52
   PubMed Web of Science ®Google Scholar
• James ND, Pirrie S, Barton D, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). ASCO Meeting Abstract. J Clin Oncol 2013;31:Suppl
   Google Scholar
• Allen BJ. Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials 2008;3:185-91
   PubMedGoogle Scholar
• Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120-5
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94
   PubMed Web of Science ®Google Scholar
• Larsen RH, Saxtorph H, Skydsgaard M, et al. Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo 2006;20:325-31
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
   PubMed Web of Science ®Google Scholar
• Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-06
   PubMed Web of Science ®Google Scholar
• Nelius T, Martinez-Marin D, Hirsch J, et al. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death and Disease 2014;5:e1210
   Google Scholar
• Furlan F, Galbiati C, Jorgensen NR, et al. Urokinase plasminogen activator receptor affects bone homeostasis by regulating OBL and OCL function. J Bone Miner Res 2007;22:1387-96
   PubMed Web of Science ®Google Scholar
• Margheri F, D’Alessio S, Serrati S, et al. Effects of blocking urokinase receptor signalling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005;12:702-14
   PubMed Web of Science ®Google Scholar
• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299-09
   PubMed Web of Science ®Google Scholar
• Ligibel JAO, Malley AJ, Fisher M, et al. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat 2012;134:1305-13
   PubMed Web of Science ®Google Scholar
• Aihara T, Suemasu K, Takei H, et al. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of NSAS BC 04, the TEAM Japan substudy. Oncology 2010;79:376-81
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-86
   PubMed Web of Science ®Google Scholar
• Deshmane V, Krishnamurthy S, Melemed AS, et al. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007;25:4967-73
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362(8):686-96
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010;3(6):696-06
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58
   PubMed Web of Science ®Google Scholar
• Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000;97:4052-7
   PubMed Web of Science ®Google Scholar
• Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92
   PubMed Web of Science ®Google Scholar
• Colnot C, Thompson Z, Miclau T, et al. Altered fracture repair in the absence of MMP9. Development 2003;130:4123-33
   PubMed Web of Science ®Google Scholar
• Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for OCL recruitment into developing long bones. J Cell Biol 2000;151:879-89
   PubMed Web of Science ®Google Scholar
• Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-22
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92
   PubMed Web of Science ®Google Scholar
• Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-03
   PubMed Web of Science ®Google Scholar
• Gonzalo P, Guadamillas MC, Hernandez-Riquer MV, et al. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell 2010;18:77-89
   PubMed Web of Science ®Google Scholar
• Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92
   PubMed Web of Science ®Google Scholar
• Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000;97:4052-7
   PubMed Web of Science ®Google Scholar
• Sabbota AL, Kim HR, Zhe X, et al. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010;70:5558-66
   PubMed Web of Science ®Google Scholar